NCT04291079: SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors

NCT04291079
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older ¬† (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have either progressive or stable disease (e.g., not improving, but not worsening, clinically or radiographically) after at least 3 cycles of treatment with an anti-PD-(L)1 antibody therapy (alone or in combination with chemotherapy) approved for that tumor type
Exclusions: Patient has symptomatic or uncontrolled brain metastases or leptomeningeal disease; Patients who have NOT received their most recent dose of anti-PD-(L)1 antibody therapy within 6 months enrollment
https://ClinicalTrials.gov/show/NCT04291079

Comments are closed.

Up ↑